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Abstract
Purpose: Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment approach for prostate
cancer. We present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after
SBRT.
Method and Materials: Between Dec. 2003 and Dec. 2005, a pooled cohort of 41 consecutive patients from
Stanford, CA and Naples, FL received SBRT with CyberKnife for clinically localized, low-risk prostate cancer.
Prescribed dose was 35-36.25 Gy in five fractions. No patient received hormone therapy. Kaplan-Meier biochemical
progression-free survival (defined using the Phoenix method) and RTOG toxicity outcomes were assessed.
Results: At a median follow-up of 5 years, the biochemical progression-free survival was 93% (95% CI = 84.7% to
100%). Acute side effects resolved within 1-3 months of treatment completion. There were no grade 4 toxicities.
No late grade 3 rectal toxicity occurred, and only one late grade 3 genitourinary toxicity occurred following
repeated urologic instrumentation.
Conclusion: Five-year results of SBRT for localized prostate cancer demonstrate the efficacy and safety of shorter
courses of high dose per fraction radiation delivered with SBRT technique. Ongoing clinical trials are underway to
further explore this treatment approach.
Background
Prostate cancer is thought to have unique radiobiology,
characterized by a low a/b ratio relative to surrounding
normal tissues [1,2]. A growing body of evidence from
clinical studies using hypofractionated radiation provides
support that the a/b ratio for prostate cancer is lower
than that for the bladder and rectum, and that conse-
quently a therapeutic gain could be achieved using
fewer, high-dose fractions (see reviews by Dasu [3] and
Macias and Biete [4]). High-dose-rate (HDR) bra-
chytherapy can deliver radiation to a tightly constrained
treatment volume using large doses per fraction. Recent
multi-institutional findings reported by Martinez et al.
for early stage prostate cancer show a 5-year biochem-
ical disease-free survival of about 90% for HDR
brachytherapy, which is comparable to their own low-
dose-rate (LDR) brachytherapy outcomes, with lower
late toxicity levels [5-7].
Stereotactic body radiotherapy (SBRT) has recently
emerged as an alternative technique to deliver hypofrac-
tionated radiotherapy to the prostate, comparable in
many respects to HDR brachytherapy, but with a non-
invasive approach [8-14]. The concept is not entirely
novel. In the 1980 s, prostate cancer patients were trea-
ted in the United Kingdom with 6 fractions of 6 Gy
each, delivered over three weeks. Good disease control
with no major early or late morbidity was obtained [15].
Innovations in image-guidance technology, the ability to
automatically correct for the movement of the prostate
during treatment, and delivery of highly-conformal
beam profiles have greatly enhanced the capability of
delivering high dose fractions to a well-defined target,
with sharp dose fall-off towards the bladder and rectum
[16-18].
King et al. at Stanford University began treating low-
risk prostate cancer patients with the CyberKnife system
( A c c u r a yI n c . ,S u n n y v a l e ,C A )i nl a t e2 0 0 3 ,u s i n gf i v e
fractions of 7.25 Gy (total 36.25 Gy). At a median
follow-up of 33 months for the first 41 patients, the
urethral/rectal toxicity profile was comparable to that
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[12]. Friedland and Freeman et al. in Naples, Florida,
began their SBRT program in early 2005, treating low-
and intermediate-risk patients with 5 fractions of 7.0 Gy
(total 35 Gy). Outcomes from their first 112 patients
showed a biochemical control rate of 97% at 24 months
median follow-up and toxicity similar to or better than
published outcomes of EBRT [9].
Given the intense level of interest in academic and
community practices, the ramifications for the manage-
ment of prostate cancer, and the potential positive eco-
nomic impact on prostate cancer treatments, we felt it
would be both timely and of significant value to exam-
ine outcomes from patients with the longest follow-up
available to date with the aim of determining disease
control and toxicity for SBRT at a median of 5 years. In
this report, we present for the first time the results from
our combined experience.
Materials and methods
Patient Characteristics
The Stanford prostate SBRT program began in Decem-
ber 2003. Eligible patients had newly diagnosed,
biopsy-proven prostate cancer presenting with low-risk
features. The criteria for low-risk classification
included a pre-treatment PSA of 10 ng/mL or less,
Gleason score of 3+3 or lower and clinical stage T1c
or T2a/b. Patients with a Gleason score of 3+4 were
included if present in 2 or fewer cores and involving
less than 5 mm aggregate tumor length. Patients with
prior treatment (hormone therapy or transurethral
resection of prostate) were excluded. The Naples pro-
spective program began in February 2005. Eligibility
criteria were similar to that of the Stanford program,
except that it included patients with Gleason scores 3
+4 in addition to those with Gleason scores of 3+3.
For the current study, we included only the Naples
patients with Gleason scores of 3+3 or lower, to
increase the homogeneity of this combined study
population. Staging work-up included a bone scan and
CT scan of the abdomen and pelvis. Both centers had
IRB-approval for enrolling patients in their clinical
trial.
The current patient cohort consists of consecutively
treated patients with the longest follow-up participating
in the Stanford [12] and Naples studies [9]. Two
patients were lost to follow-up within 12 months of
treatment and were not included. Two others died of
non-prostate cancer related disease at 12 and 51 months
after treatment. This study is therefore composed of 41
patients with a median follow-up of 5 years (4.2-6.2
years). The median patient age was 66 years (range 48
to 83 years). The median initial PSA was 5.6 ng/mL
(range 0.7 to 10 ng/mL).
Treatment Planning and Delivery
Three to four gold fiducial markers were placed in the
prostate under transrectal ultrasound guidance for
image-guided positioning and motion tracking. Treat-
ment planning CT scans were performed at a slice
thickness of 1.25 mm, either on the same day (Stanford)
or one week after fiducial placement (Naples). MRI
scans were obtained for all Naples patients, with pre-
ferred sequences of T2* GRE or T1 post Gd, using a
slice thickness of 1-2 mm. Planning CTs were used
either alone (Stanford) or fused with MRI images
(Naples), to differentiate the prostate and the proximal 1
cm of the seminal vesicles (the gross tumor volume, or
GTV) from the rectum, urogenital diaphragm, bladder,
distal seminal vesicles, and other surrounding structures.
T h ec l i n i c a lt a r g e tv o l u m ec o n s i s t e do fa3m me x p a n -
sion anteriorly and laterally and a 1 mm posterior
expansion. The planning target volume (PTV) consisted
of an additional 2 mm expansion anteriorly and laterally
and 2 mm posteriorly, to account for errors in target
definition and delivery.
All patients were treated with the CyberKnife system,
composed of a 6 MV linear accelerator mounted on a
robotic arm, with two orthogonal kilovoltage X-ray ima-
gers that provide real-time stereoscopic image guidance
and automatic correction for movements of the prostate
throughout treatment. Typically, 150-200 non-coplanar
beams were delivered in each treatment session. Patient
positioning and target tracking were accomplished by
registering the location of the fiducials in the real time
images to their location in the planning CT. The robot
automatically corrected the accelerator’s aim to account
for both translational and rotational movement of the
patient or prostate during the treatment.
Treatment for the Stanford patients consisted of 5
fractions of 7.25 Gy for a total dose of 36.25 Gy. The
prescription dose covered at least 95% of the planning
target volume, normalized to the 88-92% isodose line.
The rectal dose-volume goals were <50% of the rectum
receiving 50% of the prescribed dose, <20% receiving
80% of the dose, <10% receiving 90% of the dose, and
<5% receiving 100% of the dose. The Naples patients
received 5 fractions of 7 Gy each, for a total dose of 35
Gy. The planning objective was also to deliver the pre-
scribed dose to at least 95% of the PTV. For the rectum,
the V36 Gy constraint was <1 cm
3;f o rt h eb l a d d e r ,t h e
V37 Gy was <10 cm
3. The Stanford rectal dose-volume
guidelines were followed whenever possible. Treatments
were given over 5 consecutive days for all but 3 patients
in the combined cohort.
Follow-up and Toxicity Scoring
Patients were followed every 3 months during the first
year and every 6-12 months thereafter. PSA levels were
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measures for Stanford patients were assessed using the
EPIC scale. Naples patients were assessed with the
American Urological Association (AUA) and Sexual
Health Inventory for Men (SHIM) surveys. Toxicities
were subsequently scored based on Radiation Therapy
Oncology Group (RTOG) urinary and rectal toxicity cri-
teria [19], and toxicities requiring intervention were
noted. (The authors acknowledge that the RTOG scor-
ing system may be insensitive to subtle changes in urin-
ary or bowel function.) Biochemical failure was assessed
using the nadir+2 (Phoenix) definition [20].
Results
PSA Response
The 5-year biochemical progression-free survival rate
was 92.7% (95% CI = 84.7% to 100%, Figure 1). PSA fell
from a pre-treatment mean (± SD) of 5.4 ± 2.4 ng/ml to
a mean post-treatment value of 0.34 ± 0.35 ng/ml at last
follow-up for non-recurring patients. Median PSA nadir
was 0.3 ng/ml. Comparing non-recurring Stanford
patients (treated with 36.25 Gy) to Naples patients (trea-
ted with 35 Gy), the mean PSA at last follow-up was
significantly lower for the Stanford group (0.18 ± 0.14
ng/ml vs. 0.51 ± 0.46 ng/ml, p = 0.002). The mean fol-
low-up for the Stanford patients was about 4.5 months
longer than for the Naples patients (5.17 vs. 4.78 years).
Three patients developed biochemical progression at 33,
37 and 42 months, respectively. Two patients received
the 35 Gy dose; the third received 36.25 Gy. In each
case, biopsy confirmed pathologic evidence of malig-
nancy within the prostate gland and a negative meta-
static work-up. The remaining patients continued to
have stable or declining PSA levels at last follow-up.
Toxicity
As previously reported, patients tolerated treatments
very well, resuming normal activities within one week of
completion. Acute symptoms of dysuria, urinary
urgency, frequency, nocturia and/or tenesmus typically
resolved within one month of treatment completion.
Late toxicities are summarized in Table 1. No patient
has experienced grade 3 or greater late rectal toxicity.
Only one patient developed late grade 3 urinary toxicity
following repeated urologic instrumentation, including
cystoscopy and urethral dilatation. No urinary inconti-
nence has been observed. Twenty-five percent of
patients reported mild (grade 1) and 7% moderate
(grade 2) urinary symptoms following treatment. King et
al. [12] previously reported less frequent grade 1-2 urin-
ary toxicity when SBRT treatments were delivered on
non-consecutive days (QOD) vs. daily (QD). As the
majority of patients in this study received QD treatment,
a similar comparison was not possible.
Discussion
This report demonstrates that SBRT can achieve high
rates of durable disease control for patients with low-
risk prostate cancer while resulting in low levels of blad-
der and rectal toxicity. The current results extend prior
independently conducted studies by the authors [9,12],
demonstrating the potential of SBRT monotherapy to
provide durable disease control with few serious compli-
cations in low-risk prostate cancer patients. Our 5-year
progression-free survival rate of 93% compares favorably
with that obtained with surgery, LDR or HDR bra-
chytherapy [21-26].
In a recent update of the Stanford experience, which
included 67 low-risk patients [27], King et al. succinctly
reviewed the rationale for hypofractionation in the man-
agement of prostate cancer. At a median follow-up of
2.7 years, the PSA relapse-free survival was 94%, and
toxicity was equal to or lower than observed in dose-
escalation studies. Disease control rates above 90% are
entirely consistent with predictions based on an a/b
ratio for prostate cancer of 1.5 Gy. Using the linear-
quadratic radiobiologic model, 36.25 Gy yields an
equivalent dose at 2 Gy per fraction, or EQD2, of 91 Gy
for this a/b.
In addition, both disease control and toxicity outcomes
with SBRT compare favorably to other treatments for
Figure 1 Kaplan-Meier biochemical disease-free survival curve
after SBRT for prostate cancer. Median follow-up is 5-years. Three
of the 41 patients recurred, at 33, 37 and 42 months post-treatment.
Tick marks indicate censored patients.
Table 1 Late urinary and rectal toxicity on the RTOG
scale for prostate cancer patients after SBRT
RTOG Grade I II III IV
Urinary 25% (10/41) 7% (3/41) 2.5% (1/41) 0%
Rectal 13%
(6/41)
2.5%
(1/41)
0% 0%
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for radical prostatectomy and IMRT to a dose of at least
72 Gy [28], no significant difference in 5-year biochem-
ical disease-free survival (bDFS) rates was detected for
low-risk patients (prostatectomy resulted in a bDFS of
92.8% vs. 85.3% for IMRT, p = 0.20). Similar 5-year bDFS
rates, ranging from 76% to 92% for radical prostatectomy,
69% to 89% for external beam radiotherapy at doses of 66
to 72 Gy, and 83% to 88% for seed brachytherapy, have
been reported in retrospective comparisons of these
various treatments [21-26]. A recent report of a multi-
institutional retrospective study comparing HDR bra-
chytherapy to seed brachytherapy showed bDFS to be
about 90% for both modalities. Somewhat higher 5-year
bDFS rates, in the 92-95% range, have been obtained in
other studies of surgery, high-dose and hypofractionated
EBRT, and seed brachytherapy for low-risk patients
[29-32]. Thus, the 5-year bDFS of 92.7% obtained in the
current study is clearly within the range of disease con-
trol expected using modern surgical and high-dose radia-
tion techniques.
In the coming years, the long-term outcomes of several
other studies of SBRT for organ-confined prostate cancer
will be reported. Katz et al. reported 3-year results on
304 patients with low- and intermediate-risk disease,
with favorable outcomes [11]. An update with 42 months
median follow up was presented at ASTRO 2010 [33],
and 5-year data from this study should be available in
2011. An additional 114 low-intermediate risk prostate
patients were treated with SBRT in Naples in 2006, so
that data will reach 5-year maturity next year. Acute toxi-
city from a prospective study underway at the University
Hospitals Case Medical Center were presented at the
2009 ASCO meeting [34]. Georgetown has also treated
prostate cancer using SBRT; early data were presented at
the 2010 ASCO meeting [35]. Two prospective studies
funded by Accuray, examining the effects of delivering
either a homogeneous, EBRT-like dose distribution or an
HDR-like, heterogeneous distribution [10] should com-
plete enrollment in the next 6 months, adding another
600 patients to the collective data pool. A phase III study
comparing 12-fraction versus 5-fraction SBRT for loca-
lized prostate cancer is currently under review by the
RTOG, and a proposed, phase III study from the Univer-
sity of Miami will compare extended fractionation (26
fractions) versus accelerated hypofractionation (5 frac-
tions) for low-intermediate risk disease. As data from
these various studies mature, we will develop a clearer
picture of long-term outcomes following SBRT.
Conclusion
The current analysis is the first report of 5-year out-
comes of SBRT for low-risk prostate cancer, and bio-
chemical disease control is comparable to other
available therapies, with equal to or better toxicity pro-
files. In addition, the treatment can be completed in a
time period that is notably shorter (1-2 weeks) than
conventional radiotherapy (8-9 weeks) and neither
hospitalization nor surgical recovery is involved. These
characteristics of SBRT may benefit patients by reducing
travel costs and lost work time, allowing a more
immediate return to normal, daily routines, and poten-
tially reducing health care costs. We look forward to
future multicenter studies that will examine outcomes
with this treatment approach.
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